SCHEMBL2894154

SCHEMBL2894154

OCc1ccnc(Oc2ccccc2)c1

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 12/20 0.71
LOX P28300 9/20 0.69
LTA4H P09960 1/20 0.52
TTR P02766 1/20 0.51
FFAR1 O14842 1/20 0.48
RECQL P46063 1/20 0.46
MAPK8 P45983 1/20 0.44
MAPK10 P53779 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
RAB9A P51151 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.42
ACACB O00763 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL11361494 0.92 LOXL2 (0.61) LOXL2LOXLTA4HTTRFFAR1
SCHEMBL2885522 0.87 LOXL2 (0.67) LOXL2LOXLTA4HFFAR1MAPK8
SCHEMBL28015512 0.83 RECQL (0.51) LOXL2LOXTTRRECQLL3MBTL1
SCHEMBL18049194 0.83 LOXL2 (1.00) LOXL2LOX
SCHEMBL16453534 0.83 LOXL2 (0.71) LOXL2LOXLTA4HFFAR1SMN1; SMN2
Hydrochloric Acid SCHEMBL18049166 0.81 LOXL2 (1.00) LOXL2LOX
SCHEMBL25261490 0.80 LOXL2 (0.77) LOXL2LOXFFAR1
SCHEMBL5554530 0.79 RECQL (0.46) LOXL2LOXLTA4HRECQLSMN1; SMN2
SCHEMBL10720366 0.79 LOXL2 (0.65) LOXL2LOXFFAR1MAPK8MAPK10
Hydrochloric Acid SCHEMBL4018838 0.78 LOXL2 (0.46) LOXL2LOXLTA4HRECQLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114650868-A Small molecule degradation agent of HELIOS and use method thereof 达纳-法伯癌症研究公司 2022-06-21 CN disclosed
US-20220185815-A1 PYRROLOPYRAZOLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-06-16 US disclosed
EP-2098517-B1 NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE MSD KK (JP) 2013-12-18 EP disclosed
US-8367708-B2 Phenyl-isoxazol-3-ol derivative MSD K.K. (JP) 2013-02-05 US disclosed
US-20100130559-A1 NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-05-27 US disclosed
EP-2098517-A1 NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-09-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130559-A1 NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE GPR119, FFAR3, FFAR2 LOXL2 426/4885LOX 1540/4885LTA4H 641/4885
US-20220185815-A1 PYRROLOPYRAZOLE DERIVATIVE PTDSS1, PTDSS2, SMPD1 LOXL2 3241/4885LOX 3677/4885LTA4H 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.